Trial Profile
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Edodekin alfa (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 05 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.